Fixed-duration triplet therapy demonstrates efficacy for patients with relapsed/refractory chronic lymphocytic leukemia
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care ...
20 hours ago
0
3









